全球生物製藥安全測試市場:規模/份額/趨勢分析(按產品/服務/用途/測試類型)、區域前景、競爭戰略、按細分市場預測(至 2030 年)
市場調查報告書
商品編碼
1076144

全球生物製藥安全測試市場:規模/份額/趨勢分析(按產品/服務/用途/測試類型)、區域前景、競爭戰略、按細分市場預測(至 2030 年)

Biologics Safety Testing Market Size, Share & Trends Analysis By Product & Service, By Application, By Test Type, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 223 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球生物製藥安全檢測市場預計將以 10.8% 的複合年增長率繼續增長,到 2030 年將達到 85.6 億美元。

市場的主要驅動力是大公司在生物製藥和生物仿製藥開發方面的大量投資、新興市場的市場機會以及生物製藥外包的增加。另一方面,缺乏熟練的專家是市場上的一個主要問題。

本報告按產品/服務分析全球生物製品安全檢測市場,包括基本市場結構和主要影響因素、整體市場規模趨勢展望(2019-2030)。□我們正在按應用、研究類型調查詳細趨勢和地區、新型冠狀病毒感染 (COVID-19) 的影響以及主要公司的概況。

目錄

第 1 章介紹

第 2 章調查方法

第 3 章執行摘要

第 4 章市場概述

  • 簡介
  • 促進因素、抑制因素、市場機會、問題分析
  • 新型冠狀病毒感染 (COVID-19):生物安全性檢測市場影響

第 5 章市場變量與展望

  • SWOT分析
  • PESTEL 分析
  • 波特五力分析
  • 熱圖分析

第 6 章全球生物製藥安全檢測市場:按產品/服務(單位:100 萬美元,2019-2030)

  • 消耗品
  • 設備
  • 服務

第 7 章全球生物製藥安全檢測市場:按應用分類(單位:100 萬美元,2019-2030)

  • 血液和血液製品的製造
  • 細胞和基因治療產品的製造
  • 單克隆抗體製造
  • 其他用途
  • 疫苗製造

第 8 章全球生物製藥安全測試市場:按測試類型(單位:100 萬美元,2019-2030)

  • 生物負載測試
  • 內毒素檢測
  • 支原體檢測
  • 殘留宿主細胞衍生蛋白/DNA檢測試驗
  • 無菌測試
  • 病毒安全測試

第 9 章全球生物製藥安全檢測市場:按地區劃分(單位:100 萬美元,2019-2030)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美國家
  • 中東/非洲
    • 沙特阿拉伯王國
    • 阿拉伯聯合酋長國
    • 其他中東/非洲國家

第 10 章公司簡介

  • Agilent Technologies、Inc.
    • 公司簡介
    • 財務展望
    • 產品概覽
    • 最新趨勢
  • Almac Group
  • Associates of Cape Cod, Inc.
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories, Inc. Lonza
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Wako Pure Chemical Corporation
  • Maravai Lifesciences
  • Merck KGaA
  • Microcoat Biotechnologie GmbH
  • Nelson Laboratories, LLC
  • Pacific BioLabs
  • PromoCell GmbH
  • QIAGEN
  • Sartorius AG
  • SGS SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec
簡介目錄
Product Code: BIOT2222

The global Biologics Safety Testing Market is projected to be worth USD 8.56 billion by 2030.

According to SPER Market Research, the Biologics Safety Testing Market is estimated to reach USD 8.56 billion by 2030 with a CAGR of 10.8%.

The expansion of the biologics and biosimilars markets, increasing concerns over cell culture contamination, and rising biopharmaceuticals research & development activities and investments, emerging markets, and growing biopharmaceutical outsourcing; are the key driver for the escalation of the market.

Impact of COVID-19 on the Biologics Safety Testing Market

To provide biologics safety testing for developing safety test kits, manufacturing of vaccines testing to treat and target the infection. Pharmaceutical and biopharmaceutical companies and the biologics safety testing market have taken steps toward research in biologics safety testing.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030

Segments covered By Product, By Application, By End-User, By Region.

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa.

Companies Covered:

Agilent Technologies, Inc., Almac Group, Associates of Cape Cod, Inc. BioMerieux SA, Bio-Rad Laboratories, Inc., Charles River Laboratories, Inc., Lonza, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fujifilm Wako Pure Chemical Corporation, Maravai Lifesciences, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories, LLC, Pacific BioLabs, PromoCell GmbH, Sartorius AG, SGS SA, Thermo Fisher Scientific, Inc., WuXi AppTec.

Driver: expansion in the biosimilars and biologics markets

Heavy investments in the development of biologics and biosimilars by big companies. Growth in the biosimilars and biologics markets, Growing concerns over cell culture contamination, rising biopharmaceuticals R&D activities and investments; are the key factors, which drive the market expansion.

Opportunity: Emerging markets offer profitable opportunities

Emerging markets offer rewarding opportunities, and growing biopharmaceutical outsourcing; will provide enormous opportunities in the Biologics Safety Testing Market.

Challenges: lack of skilled professionals

Lack of skilled personnel to handle the advanced technologies and the development of new and improved safety testing.

Global Biologics Safety Testing Market, By Product & Service:

Based on the Product & Service, Global Biologics Safety Testing Market is segmented as; Consumables, Instrument, and Services.

Global Biologics Safety Testing Market, By Application:

Based on the Application, Global Biologics Safety Testing Market is segmented as; Blood and Blood Products Manufacturing, Cellular & Gene Therapy Products Manufacturing, Monoclonal Antibodies Manufacturing, and Vaccine Manufacturing.

Global Biologics Safety Testing Market, By Test Type:

Based on the Test Type, Global Biologics Safety Testing Market is segmented into; Bioburden Tests, Endotoxin tests, Mycoplasma Tests, Residual Host-cell Proteins & DNA Detection Tests, Sterility tests, and Virus safety tests.

Global Biologics Safety Testing Market, By Region:

North America dominates the biggest share of the market; this is due to the increasing academic and government investments, quick expansion in the biopharmaceutical industry, growing demand for high-quality research tools for data reproducibility, and growing alertness among consumers about product safety.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Biologics Safety Testing Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Biologics Safety Testing Market, By Product & Service, 2019-2030 (USD Million)

  • 6.1. Consumables
  • 6.2. Instrument
  • 6.3. Services

7. Global Biologics Safety Testing Market, By Application, 2019-2030 (USD Million)

  • 7.1. Blood and Blood Products Manufacturing
  • 7.2. Cellular & Gene Therapy Products Manufacturing
  • 7.3. Monoclonal Antibodies Manufacturing
  • 7.4. Other Application
  • 7.5. Vaccine Manufacturing

8. Global Biologics Safety Testing Market, By Test Type , 2019-2030 (USD Million)

  • 8.1. Bioburden Tests
  • 8.2. Endotoxin Test
  • 8.3. Mycoplasma Tests
  • 8.4. Residual Host-cell Proteins & DNA Detection Tests
  • 8.5. Sterility Test
  • 8.6. Virus safety Test

9. Global Biologics Safety Testing Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. Agilent Technologies, Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Almac Group
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Associates of Cape Cod, Inc.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BioMerieux SA
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Charles River Laboratories, Inc. Lonza
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Eurofins Scientific
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. F. Hoffmann-La Roche Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Fujifilm Wako Pure Chemical Corporation
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Maravai Lifesciences
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Merck KGaA
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Microcoat Biotechnologie GmbH
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Nelson Laboratories, LLC
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Pacific BioLabs
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. PromoCell GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. QIAGEN
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Sartorius AG
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. SGS SA
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Thermo Fisher Scientific, Inc.
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. WuXi AppTec
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments